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etaiodobenzylguanidine
maging Comes of Age
New Arrow in the Prognostic
uiver for Heart Failure Patients*
. William Strauss, MD,†
ichelle N. Johnson, MD, MPH,‡
eiko Schöder, MD,† Nagara Tamaki, MD, PHD§
ew York, New York; and Sapporo, Japan
fter an initiating event that permanently reduces cardiac
ump function, heart failure may ensue. Over time, ventric-
lar remodeling (1) occurs, cardiac output decreases, and
linical symptoms of heart failure develop. An early com-
ensatory mechanism is activation of the sympathetic ner-
ous system (2). Initially, catecholamine stimulation can
elp to compensate for decreased myocardial function.
See page 2212
ong-term catecholamine excess, however, has detrimental
ffects on myocardial structure and function. Despite ele-
ated circulating levels of catecholamines, possibly as a
rotective mechanism, norepinephrine stores in the myo-
ardium are depleted in heart failure. The reduction in
yocardial norepinephrine concentration may be due to
everal factors. Explanted hearts of patients with New York
eart Association (NYHA) functional class IV heart failure
efore transplantation demonstrated an 50% reduction in
eta-adrenergic receptor density (3). In addition to the
eduction in beta-adrenergic receptor density, laboratory
tudies demonstrate a decrease in norepinephrine trans-
orter activity (4).
This reduction in myocardial norepinephrine content
stores) can be detected by imaging with the norepinephrine
nalog meta-iodobenzylguanidine (mIBG).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Nuclear Medicine Service, Department of Radiology, and the ‡Cardi-
logy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center,i
ew York, New York; and the §Department of Nuclear Medicine, Hokkaido
niversity Graduate School of Medicine, Sapporo, Japan.evelopment of mIBG
IBG was developed to image adrenergic tumors (5). In
967, Morales et al. (6) demonstrated that the adrenal gland
oncentrated and retained 14C-labeled epinephrine. This
bservation resulted in studies of catecholamine agonists
ncluding dopamine and iodinated dopamine analogs as well
s antagonists, including the antihypertensive agent
uanethidine, as potential imaging agents to detect adrenal
edullary tumors (7). Guanethidine was particularly attrac-
ive, because of its known ability to concentrate and remain
ound in tissues with significant sympathetic innervation
including the heart) for many hours after injection (8). In
he heart, the concentration peaked at 1 h (20-fold greater
han plasma), decreasing to 18% of peak at 24 h. In 1980,
ieland et al. (9) injected dogs with 3 radioiodinated
nalogs of guanethidine: the ortho, meta, and para analogs
f iodobenzylguanidine. The metaiodo compound demon-
trated the most stable concentration. The agents had
ignificant myocardial concentration at 0.5 h, with the
etaiodo compound demonstrating better heart-to-blood
nd heart-to-lung uptake and retention than the other
gents. The myocardial uptake and retention of mIBG were
imilar to those of 14C-labeled guanethidine (10). In 1981,
study on 5 healthy volunteers demonstrated the feasibility
f imaging the human heart. The left ventricular myocar-
ium was visualized within 1 to 2 min of injection, and
etention of the tracer was documented over the 2-h
nterval of observation (11). In that report, the authors
peculate that “the agent [mIBG] could prove useful in
he evaluation of such conditions as congestive heart
ailure, ventricular hypertrophy, autonomic denervation,
nd hyperthyroidism, all of which have altered myocar-
ial catecholamine stores” (11).
mIBG is concentrated and stored in the myocardium in a
anner similar to that of norepinephrine (12). Uptake is
rimarily through the energy-requiring, temperature-
ependent, high-affinity, low-capacity, “uptake 1” norepi-
ephrine transporter mechanism (13,14). Receptors for
orepinephrine (mIBG) are located at the synapse in sym-
athetic terminal nerve axons. Once in the axon, the tracer
s transported by the vesicular monoamine transporter (15)
n the axoplasm to norepinephrine storage vesicles. In
ontrast to norepinephrine, mIBG is not catabolized by
onoamine oxidase or catechol-O-methyltransferase, both
f which are present in the synaptic cleft. As a result, the
olecule is retained, intact, in sympathetic vesicles. To
etermine the optimum time to evaluate myocardial vesic-
lar mIBG retention, Nakajo et al. (16) evaluated control
nd reserpinized rats at multiple time points. These studies
uggested 3 to 5 h (optimum at 4 h) to image the
ntravesicular compound.
yocardial Imaging With mIBG
n 1987, Rabinovitch et al. (17) described visualization of
mpaired myocardial neuronal mIBG retention in dener-
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May 18, 2010:2222–4 Meta-Iodobenzylguanidine Imagingated (autotransplanted) hearts in dogs and in animals
ubjected to high-output heart failure. These investigators
bserved decreased mIBG retention associated with de-
reased stores of myocardial norepinephrine, suggesting a
primary defect in the cardiac neuronal uptake system” in
he animals with heart failure. Henderson et al. (18) used
his information to study myocardial mIBG retention in
atients with cardiomyopathy (left ventricular ejection frac-
ion [LVEF]22%) and control subjects. The investigators
bserved reduced myocardial retention of mIBG at 4 h in
atients with cardiomyopathy compared with control sub-
ects (43% vs. 80%). The rapid mIBG clearance was con-
rmed by Tanaka et al. (19) in a separate study of patients
ith cardiomyopathy.
In 1992, the prognostic value of mIBG myocardial
etention in heart failure patients was demonstrated by
erlet et al. (20). In 90 patients followed for 1 to 27
onths, the investigators demonstrated that a heart-to-
ediastinum ratio 1.2 4 h after injection was “closely
elated to life duration and appeared to be a potent prog-
ostic index when compared to noninvasive indices of left
entricular function in either ischemic or dilated cardiomy-
pathy patients.” Since publication of the Merlet et al. (20)
tudy, a number of prognostic factors, including levels of
-type natriuretic peptide (BNP), the signal averaged elec-
rocardiogram, heart rate variability, and QT dispersion,
ave been suggested as prognostic factors in heart failure
atients. To determine whether mIBG imaging still had a
ole in prognosis, Tamaki et al. (21) enrolled 106 patients
ith an LVEF 40% (NYHA functional class II) in a
rospective study. During the 65-month follow-up, 18
atients died suddenly. Multivariate analysis demonstrated
hat mIBG washout rate and LVEF were “significantly and
ndependently associated with sudden cardiac death,
hereas signal averaged electrocardiogram, heart rate vari-
bility parameters or QT dispersion were not” (21).
Currently, the results of mIBG imaging are normalized
y measuring the ratio of myocardial mIBG uptake to the
ptake in the mediastinum (22) on early and late images.
pplying this ratio rather than measuring only the myocar-
ial activity at 2 time points reduced the requirement to
dhere to specific time points for imaging. Recently, a
etailed description of a standardized imaging procedure
nd suggested analysis for mIBG myocardial studies was
ublished (23).
he ADMIRE-HF Trial
n this issue of the Journal, Jacobson et al. (24) report the
esults of a prospective multicenter mIBG imaging trial of
61 heart failure patients recruited at 96 sites in North
merica and Europe, ADMIRE-HF (AdreView Myocar-
ial Imaging for Risk Evaluation in Heart Failure). Patients
ith NYHA functional class II and III heart failure and
VEF 35% were enrolled. Although multiple imaging
rocedures were performed, the investigators hypothesized rhat of all the parameters that could be measured, a single
arameter, the heart-to-mediastinum ratio at 4 h, would
rovide the important prognostic data. During a median
ollow-up of 17 months, 237 patients experienced 293
vents. The most frequent events were heart failure progres-
ion (n  163), nonfatal arrhythmic events (50 patients),
nd cardiac death (n  24). The authors observed that a
eart-to-mediastinum mIBG ratio of 1.6 measured 4 h
fter tracer injection provided prognostic data beyond that
vailable from LVEF, BNP assay, and NYHA functional
lass at the time of enrollment.
How could this mIBG image information be incorpo-
ated in the clinical management of patients with heart
ailure? First, scan findings may potentially help in selecting
ptimal medical therapy. The study included 74 subjects
ounger than 50 years of age with BNP 100; 47 of these
atients had high-risk heart-to-mediastinum ratios, and
ardiac events including 3 implantable cardioverter-
efibrillator activations developed in 13 subjects; there were
sudden cardiac death and 1 episode of ventricular tachy-
ardia. Thus, scan findings would identify50% of patients
t high risk with the need for aggressive medical manage-
ent in whom traditional risk factors would not have
uggested poor outcome. Although not addressed in this
tudy, an investigation of the group of patients with ejection
ractions in the 35% to 40% range in whom a significant
roportion of deaths is attributable to sudden cardiac death
ould be an interesting next step. Subgroup analysis of the
rognostic accuracy in ischemics versus nonischemics may
lso be helpful and may provide some much needed help in
he risk stratification of this latter group for whom electro-
hysiologic testing offers less reliable information. mIBG
can findings could also be helpful in patients who meet
riteria for automatic implantable cardioverter-defibrillator
mplantation but are ambivalent about this procedure, In
hese cases, mIBG scan data may provide an additional
eans of assessing overall risk of events to guide clinical
ecisions.
The ADMIRE-HF addresses the need for better risk
tratification for cardiac events in patients with left ventric-
lar dysfunction. There is a clear need for more guidance for
linicians as we seek to determine which patients with left
entricular dysfunction are at highest risk of rapid progres-
ion of heart failure, sudden cardiac death, and arrhythmic
vents. Traditional risk factors, including age, BNP levels,
-wave alternans, and the amount of myocardial scar on
maging studies and baroreceptor testing do not completely
dentify the subset of high-risk patients destined for sudden
ardiac death. ADMIRE-HF suggests a role of 123I-mIBG
cintigraphy in assessing prognosis in patients with NYHA
unctional class II and III and left ventricular dysfunction
nd supports earlier observations that the heart-to-
ediastinum ratio adds prognostic information beyond that
vailable from LVEF and BNP to predict heart failure
rogression, arrhythmia, and cardiac death. For now, this
emains a provocative finding, but future studies will have to
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Meta-Iodobenzylguanidine Imaging May 18, 2010:2222–4emonstrate that optimized medical management can in-
eed improve outcome in such high-risk patients. In this
limate of cost containment and escalating health care costs,
he ability to better assess the population at risk is crucial.
A minor criticism of the ADMIRE-HF study is the
ollimation selected for imaging mIBG. The difference in
eart-to-mediastinum ratios between high-risk and low-
isk patient groups was very small, with considerable over-
ap. Again, it will have to be shown in practice whether
canning proves really helpful in individual patients, in
articular when scan findings of the heart-to-mediastinum
atio are just above or below the threshold of 1.6. The
adiolabel in mIBG, iodine-123, emits photons at multiple
nergy levels. The most prevalent photon has an energy of
59 keV. However, there are photons at 440 keV (0.5%
bundant), 505 keV (0.4% abundant), and 529 keV (1.7%
bundant), which must be collimated to record the highest
uality images. These higher energy photons can be effec-
ively collimated with a medium energy collimator. In the
DMIRE-HF trial, the investigators used low-energy col-
imators to record the data. Low-energy collimator mIBG
mages have lower contrast than those recorded with
edium-energy collimation. Quantitation of lower contrast
mages results in lower heart-to-mediastinum ratios. It is
ossible that the results of the ADMIRE-HF trial may have
een even more striking if medium-energy collimation were
sed.
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